TicoVac (tick-borne encephalitis vaccine, whole Virus inactivated) / Pfizer - LARVOL DELTA

Fast-Track to Protection? A Review of Encepur's Express Dosing Schedule for Tick-Borne Encephalitis. (PubMed, Viruses) - "In this narrative review, we evaluate the safety and immunogenicity of Encepur's Express schedule and discuss its potential utility across a broader range of vaccinees. These insights may help inform TBE vaccine recommendations and support efforts towards improving vaccination strategies amid increasing TBE risk."

Journal • Review • CNS Disorders

Tick-borne Encephalitis in International Travelers: A Systematic Review and Vaccine Recommendations. (PubMed, J Travel Med) - "Despite recommendations for TBE vaccination for travelers to TBE endemic areas in Europe, international travel-associated TBE cases among travelers to Europe continue to occur. Most of the published travel-associated TBE cases are associated with severe clinical illness. When considering the increasing geographic spread of the TBE endemic areas and increasing TBE incidence in Europe, enhanced efforts are needed to inform appropriate international travelers about the risk of TBE and to promote vaccination of travelers to TBE endemic areas in Europe."

Journal • CNS Disorders • Infectious Disease

Tick-borne encephalitis vaccine effectiveness and public health impact in the Baltic countries of Estonia, Latvia, and Lithuania, 2019-2023. (PubMed, IJID Reg) - "TBE vaccination in Estonia, Latvia, and Lithuania was highly effective in preventing TBE. To prevent life-threatening TBE, TBE vaccine uptake and compliance with vaccination recommendations should be increased in the Baltic countries."

Journal • CNS Disorders

Incidence of Tick-Borne Encephalitis in Unvaccinated Populations Across Europe (2020-2023). (PubMed, Int J Infect Dis) - "The incidence of TBE remains a significant public health concern, with >35 million people living in highly endemic areas of Europe. TBE incidence in the unvaccinated population is substantially higher than the incidence of surveillance-reported TBE cases. Enhanced efforts are needed to increase the uptake of preventive measures including vaccination."

Journal • CNS Disorders

Tick-borne Encephalitis (TBE) in International Travelers and TBE Vaccine Recommendations for Travelers to Europe (IDWeek 2025) - No abstract available

Infectious Disease

Tick-borne encephalitis vaccine uptake, effectiveness, and impact in Sweden from 2018 to 2022. (PubMed, Sci Rep) - "In a conservative estimate, despite suboptimal compliance with TBE vaccination recommendations, vaccination averted an estimated thousand TBE cases, most resulting in hospitalization, in Sweden from 2018 to  2022. To prevent additional TBE cases in Sweden, enhanced efforts to increase TBE vaccine uptake and compliance to the TBE vaccination schedule are needed."

Journal • CNS Disorders

Public Health Impact of a Simplified Booster Vaccine Schedule Against Tick-Borne Encephalitis (TBE) in Austria: A Modeling Analysis (ISPOR-EU 2024) - "The simplified schedule would significantly reduce number of vaccine doses administered and associated AEs without a meaningful increase in TBE cases or deaths on a per year basis. This change could simplify vaccine implementation and improve uptake while achieving better public health outcomes."

CNS Disorders • Infectious Disease

Global Seroprevalence of Tick-Borne Encephalitis Antibodies in Humans, 1956-2022: A Literature Review and Meta-Analysis. (PubMed, Vaccines (Basel)) - "Despite the availability of tick-borne encephalitis (TBE) vaccines, the incidence of TBE is increasing...Between 1956-1991 and 1992-2022, anti-TBEV seroprevalence remained at ~2.75% across all population groups from "high-risk" areas (p = 0.458) but decreased within general populations (1.7% to 1%; p = 0.001) and high-risk populations (5.1% to 1.3%; p < 0.001), possibly due to differences in the study methodologies between periods. This global summary explores how serological methods can be used to assess TBE vaccination coverage and potential exposure to TBEV or measure TBE burden and highlights the need for standardized methodology when conducting TBE seroprevalence studies to compare across populations."

Journal • Retrospective data • Review • CNS Disorders • Infectious Disease

Effectiveness of Vaccination Against Tick-Borne Encephalitis in the Czech Republic, 2018-2022. (PubMed, Vector Borne Zoonotic Dis) - "Vaccination averted hundreds of TBE cases and hospitalizations despite the relatively low compliance with TBE vaccine recommendations. To prevent additional TBE cases in the Czech Republic, enhanced efforts to increase TBE vaccine uptake are needed."

Journal • CNS Disorders • Infectious Disease • Inflammation

0860 - PRODUCT THEATRE 02 (Not included in the main event CME/CPD credit) - What you should know about TBE and tick-borne diseases in children (ESPID 2024) - "Supported by Pfizer. This product theater will highlight tick-borne encephalitis prevention and TicoVac Junior to the pediatric community.The topics covered will give an overview on the risk of tick-borne pathogen infection including TBE and Borrelia, prevention methods and then focus on the clinical manifestations of TBE, vaccine effectiveness, and impact."

Clinical • CME • CNS Disorders • Infectious Disease • Lyme Disease • Pediatrics

Phase 3 immunogenicity and safety study of a tick-borne encephalitis vaccine in healthy Japanese participants 1 year of age and older. (PubMed, Vaccine) - P3 | "TBE vaccine elicited robust immune responses in Japanese participants 1 year of age and older. The 3-dose regimen was safe and well tolerated, and findings were consistent with the known safety profile of this TBE vaccine."

Journal • P3 data • CNS Disorders • Pediatrics

Evidence for a 10-year TBE vaccine booster interval: an evaluation of current data. (PubMed, Expert Rev Vaccines) - "Long-term immunogenicity data for Encepur and real-world data on vaccine effectiveness and breakthrough infections following the two European TBE vaccines, Encepur and FSME-Immun, have shown that extending the booster interval from 3-5 years to 10 years does not negatively impact protection against TBE, regardless of age. Such extension not only streamlines the vaccination schedules but may also increase vaccine uptake and compliance among those living in endemic regions."

Journal • Review • CNS Disorders • Infectious Disease

Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in Children (clinicaltrials.gov) - P3 | N=302 | Completed | Sponsor: Pfizer | Phase classification: P3b ➔ P3

Phase classification • CNS Disorders

Primary TBE Vaccination for the Elderly (clinicaltrials.gov) - P4 | N=90 | Not yet recruiting | Sponsor: Region Örebro County

Trial completion date • Trial primary completion date • CNS Disorders

Tick-Borne Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023. (PubMed, MMWR Recomm Rep) - "In August 2021, the Food and Drug Administration approved Ticovac TBE vaccine for use among persons aged ≥1 year. This report summarizes the epidemiology of and risks for infection with TBE virus, provides information on the immunogenicity and safety of TBE vaccine, and summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of TBE vaccine among U.S. travelers and laboratory workers."

Journal • CNS Disorders • Infectious Disease • Solid Organ Transplantation • Transplantation

A systematic literature review of the effectiveness of tick-borne encephalitis vaccines in Europe. (PubMed, Vaccine) - "Published VE studies demonstrate a high real-world effectiveness of the commercially available TBE vaccines in Europe. Although cases averted have been estimated in only four countries, TBE vaccination prevents thousands of cases in Europe each year. To prevent life-threatening TBE, TBE vaccine uptake and compliance with the vaccination schedule should be increased in residents of, and travelers to, TBE-endemic countries in Europe."

Journal • Review • CNS Disorders • Infectious Disease • Inflammation

Induction of humoral and cell-mediated immunity to the NS1 protein of TBEV with recombinant Influenza virus and MVA affords partial protection against lethal TBEV infection in mice. (PubMed, Front Immunol) - "Upon heterologous prime/boost regimens partial protection against lethal TBEV challenge infection was afforded in mice. This supports the inclusion of NS1 as a vaccine component in next generation TBEV vaccines."

Journal • Preclinical • CNS Disorders • Infectious Disease • Influenza • Respiratory Diseases

Effectiveness of tick-borne encephalitis vaccination in Latvia, 2018-2020: an observational study. (PubMed, Clin Microbiol Infect) - "TBE vaccine was highly effective in preventing TBE, moderate and severe disease, and prolonged hospitalisation. To prevent life-threatening TBE, TBE vaccine uptake and compliance should be increased in Latvia and other European regions where TBE is endemic."

Journal • Observational data • CNS Disorders • Infectious Disease • Inflammation

Effectiveness of Tick-borne Encephalitis Vaccines in Children, Latvia, 2018-2020. (PubMed, Pediatr Infect Dis J) - "Pediatric TBE vaccines were highly effective in preventing TBE in children. Increasing TBE vaccine uptake in children is essential to maximize the public health impact of TBE vaccination."

Journal • CNS Disorders • Infectious Disease • Inflammation • Pediatrics

Increased Vaccination Diversity Leads to Higher and Less-Variable Neutralization of TBE Viruses of the European Subtype. (PubMed, Vaccines (Basel)) - "Although all sera were able to neutralize the TBEV-EU strains, there were significant differences among the various vaccination groups. The neutralization assays revealed that the vaccination using the two different vaccine brands significantly increased neutralization titers, decreased intra-serum variance, and reduced the inter-virus variation."

Journal • CNS Disorders • Infectious Disease • Transplantation

VACCINE EFFECTIVENESS OF FSME-IMMUN JUNIOR FOR THE PREVENTION OF TICK-BORNE ENCEPHALITIS (TBE) IN CHILDREN 1-15 YEARS OF AGE IN LATVIA, 2018-2020 (ESPID 2023) - "In Latvia, pediatric TBE vaccines, including FSME-IMMUN Junior (FSME-Jr), are recommended, and partially government-reimbursed, for children 1-15 years-of-age but TBE vaccine effectiveness (VE) in children has not been reported... From 2018-2020, surveillance identified 36 TBE cases in children 1-15 years-of-age; all cases were hospitalized, 5 (14%) for >12 days. TBE incidence in children 1-15 years-of-age was 4.0/100,000 population per year. Of the TBE cases, 34 (94%) were unvaccinated, 1 (3%) was FSME-Jr fully-vaccinated, and 1 (3%%) was partially-vaccinated."

Clinical • CNS Disorders • Infectious Disease • Pediatrics

A recombinant Modified Vaccinia virus Ankara expressing prME of tick-borne encephalitis virus affords mice full protection against TBEV infection. (PubMed, Front Immunol) - "MVA-prME was tested in mice in comparison with a licensed vaccine FSME-IMMUN® and proved to be highly immunogenic and afforded full protection against challenge infection with TBEV. Our data indicate that MVA-prME holds promise as an improved next-generation vaccine for the prevention of TBE."

Journal • Preclinical • CNS Disorders • Infectious Disease

Five accelerated schedules for the tick-borne encephalitis vaccine FSME-Immun® in last-minute travellers: an open-label, single-Centre, randomized controlled pilot trial. (PubMed, J Travel Med) - "The accelerated two-visit ID schedules might offer a better immunological alternative to the recommended classical accelerated IM schedule but an aluminium-free vaccine would preferable."

Journal • CNS Disorders

Vaccine effectiveness of FSME-IMMUN for the prevention of hospitalised tickborne encephalitis (TBE) and severe TBE infection in Latvia, 2018-2020 (ECCMID 2023) - No abstract available

Clinical • CNS Disorders • Infectious Disease • Tuberculosis

A Phase 3, Single-Arm, Open-Label Study to Evaluate the Immunogenicity, Safety, and Tolerability of a (Tick Borne Encephalitis) TBE Vaccine in Healthy Japanese Participants 1 Year of Age and Older (clinicaltrialsregister.eu) - P3 | N=165 | Sponsor: Pfizer Inc.

New P3 trial • CNS Disorders • Infectious Disease